Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physiological Anticoagulant Deficiencies: Pathogenesis, Diagnosis, and Clinical Implications.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Systematic Review and Meta-analysis on the Efficacy and Safety of Low Dose Anticoagulation Compared with Therapeutic Dose in the Extended Secondary Prophylaxis of Venous Thromboembolism.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2026
Same author

New approaches in the haemostatic management of postpartum haemorrhage.

BMJ medicine·2026
Same author

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same author

Use of andexanet alfa: A British Society for Haematology position statement.

British journal of haematology·2026
Same author

Global survey of women's awareness of pregnancy- and postpartum-associated venous thromboembolism (World Thrombosis Day 2025).

Research and practice in thrombosis and haemostasis·2026
Same journal

Correction: VExUS score: optimizing its use in perioperative and critical care management.

Critical care (London, England)·2026
Same journal

Optimizing β-lactam antibiotics with the highest concentration-for continuous infusion reduce carbon footprint in intensive care.

Critical care (London, England)·2026
Same journal

Physiological and clinical effects of selected airway clearance techniques in mechanically ventilated adult ICU patients: a systematic review and synthesis without meta-analysis.

Critical care (London, England)·2026
Same journal

How we use the neurological pupil index (NPi).

Critical care (London, England)·2026
Same journal

45th International Symposium on Intensive Care & Emergency Medicine.

Critical care (London, England)·2026
Same journal

High-resolution monitoring reveals fragmented 24-hour light exposure in intensive care units.

Critical care (London, England)·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Tranexamic acid: less bleeding and less thrombosis?

Anne Godier, Ian Roberts, Beverley J Hunt

    Critical Care (London, England)
    |July 4, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Early tranexamic acid (TXA) administration in trauma patients lowers mortality without increasing clot risk. This commentary proposes TXA may possess antithrombotic properties, potentially through anti-inflammatory and platelet effects.

    More Related Videos

    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
    08:01

    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

    Published on: February 27, 2026

    Related Experiment Videos

    Last Updated: May 20, 2026

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
    08:13

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

    Published on: September 30, 2021

    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
    08:01

    The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

    Published on: February 27, 2026

    Area of Science:

    • Trauma and Emergency Medicine
    • Pharmacology
    • Hematology

    Background:

    • Early tranexamic acid (TXA) administration is proven to reduce mortality in bleeding trauma patients.
    • Concerns exist regarding TXA's potential to increase thrombotic events.
    • Existing evidence suggests TXA may not increase, and could potentially decrease, arterial thrombosis risk.

    Purpose of the Study:

    • To hypothesize that tranexamic acid (TXA) possesses antithrombotic effects.
    • To explore potential mechanisms underlying TXA's proposed antithrombotic activity.
    • To discuss the implications of TXA's antithrombotic potential for its systemic use in surgery.

    Main Methods:

    • This is a commentary and hypothesis-driven exploration, not an experimental study.
    • Mechanisms explored include inhibition of plasmin's inflammatory effects.
    • Potential effects on platelet function and coagulation factors V and VIII are examined.

    Main Results:

    • TXA reduces all-cause mortality in bleeding trauma patients.
    • TXA does not appear to increase the risk of vascular occlusive events.
    • The risk of arterial thrombosis may be reduced by TXA administration.

    Conclusions:

    • TXA may possess inherent antithrombotic properties.
    • Potential mechanisms involve modulation of inflammation, platelets, and coagulation factors.
    • Confirmation of these antithrombotic effects could expand TXA's use in surgical bleeding management.